Physician profile
John G Preddy
NPI 1922064955
$838.52
in general payments reported to CMS, 2019-2025
13 companies · $139 in 2025
The $139 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $112 · 2022: $164 · 2023: $116 · 2024: $308 · 2025: $139.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $562.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $562.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $227.55 | 2024-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $117.79 | 2022-2025 | Austedo Xr, Uzedy, Austedo |
| Sunovion Pharmaceuticals INC. | $112.13 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $86.95 | 2022-2024 | Rexulti |
| Ucb, INC. | $65.93 | 2024 | Nayzilam |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $56.26 | 2022 | |
| Novartis Pharmaceuticals Corporation | $36.83 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.67 | 2023-2024 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $28.52 | 2024 | Airsupra |
| Acadia Pharmaceuticals INC | $27.87 | 2022 | |
| Amgen INC. | $21.31 | 2025 | Evenity, Prolia |
| Lundbeck LLC | $13.82 | 2023 | Rexulti |
| Sumitomo Pharma America, INC. | $11.89 | 2023 | Aptiom |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Preddy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.